Company · founded 2017
Allogene Therapeutics (United States)
San Francisco, United States · allogene.com
- Citations, last 5 years
- 947
- Works, last 5 years
- 56
- h-index
- 57
- Scientists listed
- 12
- Grants since 2016
- 6
Grants received
2022–2026 · research · R44
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
Reeder Mcneil Robinson · Allogene Therapeutics (United States) · funded by National Institutes of Health
2022–2026 · research · R44
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
Reeder Mcneil Robinson · Allogene Therapeutics (United States) · funded by National Institutes of Health
2022–2023 · research · R42
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
Reeder Mcneil Robinson · Allogene Therapeutics (United States) · funded by National Institutes of Health
2022–2026 · research · R44
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
Reeder Mcneil Robinson · Allogene Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R41
Bispecific T cell engagers for the treatment of pancreatic ductal adenocarcinoma
Nathan G. Dolloff · Allogene Therapeutics (United States) · funded by National Institutes of Health
2016–2018 · research · R41
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
Frank W. Marcoux · Allogene Therapeutics (United States) · funded by National Institutes of Health